USA - NASDAQ:RMTI - US7743743004 - Common Stock
The current stock price of RMTI is 1.14 USD. In the past month the price decreased by -10.24%. In the past year, price decreased by -69.92%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 25.2 | 38.03B | ||
| COO | COOPER COS INC/THE | 18.12 | 14.48B | ||
| SOLV | SOLVENTUM CORP | 11.84 | 12.48B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.42 | 9.83B | ||
| BLCO | BAUSCH + LOMB CORP | 36.6 | 5.44B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.61 | 4.90B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.1 | 3.95B | ||
| ICUI | ICU MEDICAL INC | 16.34 | 3.03B | ||
| XRAY | DENTSPLY SIRONA INC | 7.65 | 2.61B | ||
| HAE | HAEMONETICS CORP/MASS | 11.01 | 2.47B | ||
| UFPT | UFP TECHNOLOGIES INC | 23.18 | 1.54B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.47B |
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 244 full-time employees. The firm develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The firm operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The firm is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The firm manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
ROCKWELL MEDICAL INC
30142 Wixom Road
Wixom MICHIGAN 48393 US
CEO: Russell Ellison
Employees: 244
Phone: 18004493353
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 244 full-time employees. The firm develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The firm operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The firm is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The firm manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
The current stock price of RMTI is 1.14 USD. The price decreased by -1.72% in the last trading session.
RMTI does not pay a dividend.
RMTI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
ROCKWELL MEDICAL INC (RMTI) currently has 244 employees.
ROCKWELL MEDICAL INC (RMTI) will report earnings on 2025-11-12.
ChartMill assigns a technical rating of 1 / 10 to RMTI. When comparing the yearly performance of all stocks, RMTI is a bad performer in the overall market: 92% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to RMTI. The financial health of RMTI is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months RMTI reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 64.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.99% | ||
| ROE | -6.9% | ||
| Debt/Equity | 0.33 |
8 analysts have analysed RMTI and the average price target is 4.08 USD. This implies a price increase of 257.89% is expected in the next year compared to the current price of 1.14.
For the next year, analysts expect an EPS growth of -750% and a revenue growth -31.95% for RMTI